Actinium Pharmaceuticals’ Actinium’s Antibody Warhead Enabling (AWE) platform
Website: https://mellalta.com/actiniums-multi-billion-dollar-market-for-targeted-conditioning-with-their-revolutionary-antibody-warhead-enabling-awe-platform/

Actiniums Significant investment in R&D and AWE platform since 2018 and as a World leader in Ac-225 R&D with comprehensive IP portfolio is looking forward for next generation empowered antibodies through its AWE platform and different ARCs capabilities which is very ideal for multiple area of development.

In 2018, Actinium went into a collaborative research partnership with Astellas Pharma, Inc. that leverages Actinium’s AWE Technology Platform. Conjugation of Daratumumab with 225Actinium under the AWE platform has already showed some gigantic efficacy, greatly increasing its antitumor activity against Multiple Myeloma Tumors.

Market Attractiveness for Targeted Conditioning Platform

Actinium’s clinical program which are still ongoing have already shown some high efficacy and what we, Mellalta Meets could say, that the promising new platform of AWE based target conditioning therapies and their unique combination approach is going to be something to keep an eye for, as the company looks for BLA submission for its lead product by 2021-2022.

Search Keywords / Tags: Actinium’s Iomab-B,

 

 

Related Business Listings

Best Gastro Doctor in H
Best Cancer Specialist
Kidney Stones Treatment
Goh Hak Su Colon & Rect
Stem Cell Care India
The Surgeons - Colon an
Cornea Specialist in Mu
Retinal Detachment Surg
Book Online Medical Con